![Chemical structure of 1,3-Diazaspiro[4.4]non-1-en-4-one, 2-butyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, CAS 138402-11-6](https://api.angenesci.com/structure/2372/138402-11-6.png)
无数据
无数据
无数据
| CAS Number | 138402-11-6 |
| Catalog Number | AG0018Q6(AGN-PC-0PMNVE) |
| Chemical Name | 1,3-Diazaspiro[4.4]non-1-en-4-one, 2-butyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- |
| EC Number | 604-078-2 |
| IUPAC Name | 2-butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one |
| InChI | InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30) |
| InChI Key | YOSHYTLCDANDAN-UHFFFAOYSA-N |
| MDL Number | MFCD00864464 |
| Molecular Formula | C25H28N6O |
| Molecular Weight | 428.5294 |
| NSC Number | 758696 |
| SMILES | O=C1C2(N=C(N1Cc1ccc(cc1)c1c(cccc1)c1[nH]nnn1)CCCC)CCCC2 |
| UNII | J0E2756Z7N |
| Synonyms | 2-n-butyl-3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1,3-diazaspiro(4,4)non-1-en-4-one,
Aprovel,
Avapro,
BMS 186295,
BMS-186295,
irbesartan,
Karvea,
SR 47436,
SR-47436,
SR47436,
irbesartan,
138402-11-6,
Aprovel,
Avapro,
Karvea,
SR-47436,
BMS-186295,
BMS 186295,
Irbesartan [USAN:INN],
SR 47436,
UNII-J0E2756Z7N,
CHEMBL1513,
8-butyl-7-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-7,9-diazaspiro[4.4]non-8-en-6-one,
CHEBI:5959,
C25H28N6O,
YOSHYTLCDANDAN-UHFFFAOYSA-N,
J0E2756Z7N,
MFCD00864464,
2-butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one,
3-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one,
NCGC00095122-01,
AK-57149,
DSSTox_CID_3169,
2-Butyl-3-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-1,3-diazaspiro(4.4)non-1-en-4-one,
2-Butyl-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]1,3-diaza-spiro[4.4]non-1-en-4-one,
2-butyl-3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4.4]non-1-en-4-one,
DSSTox_RID_76900,
DSSTox_GSID_23169,
1,3-Diazaspiro(4.4)non-1-en-4-one, 2-butyl-3-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-,
1,3-Diazaspiro[4.4]non-1-en-4-one, 2-butyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-,
Irbesarran,
Lrbesartan,
Irbetan,
Irbesartan Krka,
Irbesartan BMS,
[3H]irbesartan,
Irbesartan Winthrop,
2-BUTYL-3-[[2'-(2H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-1,3-DIAZASPIRO[4.4]NON-1-EN-4-ONE,
SMR000466306,
Avapro (TN),
CAS-138402-11-6,
HSDB 8215,
Irbesartan [USAN:USP:INN:BAN],
Irbesartan(Avapro),
Irbesartan ,(S),
2-butyl-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one,
2-butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one,
3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one,
Irbesartan (Avapro),
Irbesartan(Avapro)/,
PubChem21382,
Spectrum_001751,
AC1L1GMK,
Spectrum2_001675,
Spectrum3_000994,
Spectrum4_001122,
Spectrum5_001288,
SCHEMBL4246,
2-n-butyl-3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1,3-diazaspiro(4,4)non-1-en-4-one,
BSPBio_002687,
GTPL589,
KBioGR_001603,
KBioSS_002231,
MLS000759408,
MLS001424099,
BIDD:GT0347,
SPECTRUM1504259,
SPBio_001889,
GTPL6908,
Jsp002315,
DTXSID0023169,
Irbesartan (JP17/USAN/INN),
KBio2_002231,
KBio2_004799,
KBio2_007367,
KBio3_001907,
KS-00000ISW,
EBD8758,
BCPP000202,
HMS1922J05,
HMS2051L08,
HMS2093E16,
HMS2232F23,
HMS3370B06,
HMS3393L08,
HMS3715L04,
Pharmakon1600-01504259,
BCP02004,
HY-B0202,
ZINC3872931,
Tox21_111433,
ABP000523,
AC-537,
BDBM50042235,
CCG-39091,
NSC758696,
STK645362,
AKOS005576396,
AKOS015895353,
Irbesartan, >=98% (HPLC), powder,
Tox21_111433_1,
AB07472,
AM90289,
BCP9000792,
CCG-101012,
CS-2140,
DB01029,
KS-1151,
MCULE-9617953373,
NC00262,
NSC-758696,
NCGC00095122-02,
NCGC00095122-03,
NCGC00095122-05,
2-butyl-3-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one,
4CA-0654,
AN-15743,
BC207567,
BR-57149,
CPD000466306,
H931,
LS-60064,
SAM001246548,
SC-08814,
SBI-0206769.P001,
AB0013366,
AB1009632,
TL8000875,
FT-0601598,
I0859,
S1507,
ST24028252,
C07469,
D00523,
J10394,
S-1797,
54246-EP2270011A1,
54246-EP2295406A1,
54246-EP2295422A2,
54246-EP2298772A1,
54246-EP2298776A1,
54246-EP2298779A1,
54246-EP2301923A1,
54246-EP2301931A1,
54246-EP2305219A1,
54246-EP2308562A2,
54246-EP2308839A1,
AB00639954-06,
AB00639954_07,
AB00639954_08,
402I116,
A807387,
L000319,
SR-05000001997,
I06-0690,
Q-201249,
SR-05000001997-1,
(-)-Styrene glycol; (R)-(-)-Phenylethylene glycol,
BRD-K60038276-001-02-5,
BRD-K60038276-001-03-3,
Irbesartan, European Pharmacopoeia (EP) Reference Standard,
Irbesartan, United States Pharmacopeia (USP) Reference Standard,
2-butyl-3-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-1,3-diaza-spiro[,
2-butyl-3-[2'-(1h-tetrazol-5-yl)biphenyl-4-ylmethyl]1,3-diaza-spiro[,
Irbesartan, Pharmaceutical Secondary Standard; Certified Reference Material,
2-butyl-3-[ p -( o -1 H -tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4,4]non-1-en-4-one,
2-(n-butyl)-3-[[2'-(tetrazol-5-yl)biphenyl-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one,
2-butyl-3-({4-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1,3-diazaspiro[4.4]non-1-en-4-one,
2-butyl-3-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1,3-diazaspiro[4.4]non-1-en-4-one,
2-Butyl-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-1,3-diaza-spiro[4.4]non-1-en-4-one,
2-butyl-3-{[2''-(1H-tetrazol-5-yl)[1,1''-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one,
2-butyl-3-{[2''-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one,
2-n-butyl-3-<<2'-(1H-tetrazol-5-yl)biphenyl-4-yl>methyl>-1,3-diazaspiro<4.4>non-1-en-4-one;,
3-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one,
3-((2'-(2H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one,
8-butyl-7-[[4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]-7,9-diazaspiro[4.4]non-8-en-6-one,
Avalide,
ifirmasta,
Sabervel,
Irbesartan HCl,
Irbesartan D4,
Irbesartan Zentiva,
Aprovel (TN),
Avalide (TN),
Karvea (TN),
Irbesartan hydrochloride,
2,4-Dichloropyrimidine,
BMS Brand of Irbesartan,
D00JAU,
D0F8KG,
Irbesartan (JAN/USAN/INN),
CID3749,
Bristol Myers Brand of Irbesartan,
SanofiWinthrop Brand of Irbesartan,
C25-H28-N6-O,
CS-T-29592,
SR47436,
A5970,
A10477,
C081309,
BMS-186295, SR-47436,Aprovel, Karvea, Irbesartan,
D000077405,
3-BUTYL-2-[[4-[2-(2H-TETRAZOL-5-YL)PHENYL]PHENYL]METHYL]-2,4-DIAZASPIRO[4.4]NON-3-EN-1-ONE,
2-butyl-3-[ p-(o-1 H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4,4]non-1-en-4-one,
3-butyl-2-((4-(2-(2h-tetrazol-5-yl)phenyl)phenyl)methyl)-2,4-diazaspiro(4.4)non-3-en-1-one,
Irbesartan, 99%, a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist - 1G 1g,
|
| Complexity | 682 |
| Compound Is Canonicalized | Yes |
| Covalently-Bonded Unit Count | 1 |
| Defined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Exact Mass | 428.232g/mol |
| Formal Charge | 0 |
| Heavy Atom Count | 32 |
| Hydrogen Bond Acceptor Count | 5 |
| Hydrogen Bond Donor Count | 1 |
| Isotope Atom Count | 0 |
| Molecular Weight | 428.54g/mol |
| Monoisotopic Mass | 428.232g/mol |
| Rotatable Bond Count | 7 |
| Topological Polar Surface Area | 87.1A^2 |
| Undefined Atom Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| XLogP3 | 4.1 |
| Symbol: | |
| Hazard Class | |
| Hazard statements | H302-H315-H319-H335 |
| Packing Group | |
| Precautionary statements | P261-P305+P351+P338 |
| UN Code |
| Chemical Name: | Batch Number: | |
| Chemical Structure: | CAS Registry No: | |
| Product ID: | ||
| Manufacture Date: | ||
| Storage Temperature: | ||
| Formula: | ||
| Molecular Weight: | ||
| Quantity: |
| Test: | Result: |

